Author:
Han Seunga,Suzuki-Kerr Haruna,Vlajkovic Srdjan M.,Thorne Peter R.
Abstract
AbstractSince the discovery of ATP as an extracellular signalling molecule in 1972, purinergic signalling, mediated by extracellular purines and pyrimidines has been identified in virtually all mammalian tissues and is implicated in regulating fundamental cellular processes. In recent years, there has been an increasing focus on the pathophysiology and potential therapeutic interventions based on purinergic signalling. A vast range of compounds targeting purine receptors are in clinical development, and many more are in preclinical studies, which highlights the fast growth in this research field. As a tribute to Professor Geoffrey Burnstock’s legacy in purinergic signalling, we present here a brief review of compounds targeting purine receptors that are in different stages of clinical trials. The review highlights the 50-year journey from basic research on purinergic receptors to clinical applications of therapies targeting purine receptors.
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Cellular and Molecular Neuroscience,Molecular Biology
Reference119 articles.
1. Burnstock G (1972) Purinergic nerves. Pharmacol Rev 24(3):509–581
2. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50(3):413–492
3. Burnstock G, Knight GE (2004) Cellular distributions and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240:31–304
4. Burnstock G (2016) Short- and long-term (trophic) purinergic signaling. Philos Trans R Soc B 371(1700):20150422
5. Huang Z, Xie N, Illes P, Di Virgilio F, Ulrich H, Semyanov A, Verkhratsky A, Sperlagh B, Yu SG, Huang C, Tang Y (2021) From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther 6(1):162
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献